PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33810348-0	2021	In Silico Design and Selection of New Tetrahydroisoquinoline-Based CD44 Antagonist Candidates.	1,2,3,4-tetrahydroisoquinoline	38-60	CD44 molecule (Indian blood group)	Homo sapiens	67-71	
34952427-9	2022	CCK-8 assay was used to show MTX-resistant CRC cell viability following CD44 inhibitor (THIQ) and AGT inhibitor (O6-BG) treatments.	1,2,3,4-tetrahydroisoquinoline	88-92	CD44 molecule (Indian blood group)	Homo sapiens	72-76	
34952427-15	2022	This research screened out CD44 and AGT in MTX-resistant CRC cells by bioinformatics and suggested that the combination of MTX with O6-BG or THIQ could enhance the sensitivity of MTX-resistant CRC cells to MTX.	1,2,3,4-tetrahydroisoquinoline	141-145	CD44 molecule (Indian blood group)	Homo sapiens	27-31	
31953176-4	2020	We observed that inhibition of CD44 by using 1,2,3,4 tetrahydroisoquinoline (THIQ) modulates the expression of Wnt/ beta-catenin signaling proteins and further silencing of beta-catenin also decreases the expression of CD44.	1,2,3,4-tetrahydroisoquinoline	45-75	CD44 molecule (Indian blood group)	Homo sapiens	31-35